Orexigen Data On Contrave Cannot Be Trusted, Top FDA Official Says
Orexigen Data On Contrave Cannot Be Trusted. A top U.S. Food and Drug Administration official says data showing that Orexigen’s obesity drug Contrave reduces the risk of heart attacks and cardiovascular death cannot be relied upon. Forbes reports that John Jenkins, director of the office of New Drugs, called the results … [Read more...] about Orexigen Data On Contrave Cannot Be Trusted, Top FDA Official Says
Study Results on Cardiovascular Risks for Obesity Drug May be “Unreliable,” FDA Says
Study results showing that Orexigen’s obesity drug Contrave reduced the risk of heart attacks were probably “unreliable,” “misleading,” and “likely false,” according to a top official at the Food and Drug Administration (FDA). Orexigen released the Contrave data as part of a patent filing with the Securities and Exchange … [Read more...] about Study Results on Cardiovascular Risks for Obesity Drug May be “Unreliable,” FDA Says
